Inclusion Criteria:~* Male or female, aged 55-85 years (both inclusive) at the time of signing informed
consent.~* MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type according to the NIA-AA
(National Institute of Aging-Alzheimer's Association) 2018 criteria.~* CDR (Clinical Dementia Rating) global
score of 0.5 and CDR of 0.5 or more in at least one of the three instrumental activities of daily living
categories (personal care, home \& hobbies, community affairs) Or CDR global score of 1.0~* RBANS (Repeatable
Battery for the Assessment of Neuropsychological Status) delayed memory index score of below or equal to 85~*
MMSE (Mini-Mental State Examination) greater than or equal to 22~* Amyloid positivity established with either
amyloid PET (positron emission tomography), CSF (cerebrospinal fluid) AÎ²1-42 or CSF AÎ²1-42/AÎ²1-40 .~* If
receiving an approved Alzheimer's disease treatment (such as acetylcholinesterase inhibitors, memantine or
aducanumab) the dose must have been stable for at least 3 months prior to screening and should not be changed
during the trial unless medically necessary.~
